LBR-101 Low Dose

DRUG2 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Chronic MigraineEpisodic Migraine Headache

Phase 2

Assessment of LBR-101 In Chronic Migraine

CompletedNCT02021773

Teva Branded Pharmaceutical Products R&D, Inc.Chronic Migraine

Start: 2014-01-31End: 2015-03-31Updated: 2021-12-09

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

CompletedNCT02025556

Teva Branded Pharmaceutical Products R&D, Inc.Episodic Migraine Headache

Start: 2014-01-31End: 2015-03-31Updated: 2022-01-24

Related Papers

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post‐Hoc Analyses on the First 3 Weeks of Treatment

Headache The Journal of Head and Face Pain2018-11-1847 citations

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.

2018-08-1728 citations

Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials

Cephalalgia2018-05-0328 citations

Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines

Headache The Journal of Head and Face Pain2017-09-0147 citations

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

2015-09-30205 citations

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

2015-09-30198 citations